FAX COVER SHEET

To: Jeffrey Epstein / Lesley

From: Lisa

Company:

Company: Woodson Merrell MD PLLC

Fax: [redacted]

Phone: [redacted]

Date: 9/18/2018

Pages w/cover: 11

Subject:

9-14-18 LABCORP (Partial) Lab Re

Comments:

LabCorp **Patient Report**

Specimen ID: 257-480-2371-0
Control ID: F5B31143092

Acct #: 31143092 Phone: [redacted] Rte: 68

EPSTEIN, JEFFREY
9 E 71ST ST
NEW YORK NY 10021
[redacted]

Woodson Merrell
44 E 67th St
New York NY 10065

Patient Details
DOB: 01/20/1953
Age(y/m/d): 065/07/25
Gender: M SSN:
Patient ID:

Specimen Details
Date collected: 09/14/2018 1255 Local
Date received: 09/15/2018
Date entered: 09/15/2018
Date reported: 09/18/2018 0610 ET

Physician Details
Ordering: W MERRELL
Referring:
ID: MERRELL
NPI: 1023153509

General Comments & Additional Information
Total Volume: Not Provided **Fasting:** No

Ordered Items
CBC With Differential/Platelet; Comp. Metabolic Panel (14); Urinalysis, Routine; PE+Interp(Rfx IFE),S; Lipid Panel; Iron and TIBC; Testosterone,Free+Weakly Bound; Vitamin B12 and Folate; FSH and LH; C-Reactive Protein, Cardiac; Hemoglobin A1c; Prostate-Specific Ag, Serum; TSH; Vitamin D, 25-Hydroxy; Lipoprotein (a); IGF-1; ANA w/Reflex; Homocyst(e)ine, Plasma; Prolactin; Thyroxine (T4) Free, Direct, S; Cortisol; DHEA-Sulfate; Estradiol; Uric Acid; Phosphorus; LDH; GGT; Amylase; Ferritin, Serum; Insulin; Calcium, Ionized, Serum; Fibrinogen Activity; Magnesium, RBC

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
CBC With Differential/Platelet					
WBC	5.7		x10E3/uL	3.4 - 10.8	01
RBC	4.90		x10E6/uL	4.14 - 5.80	01
Hemoglobin	14.7		g/dL	13.0 - 17.7	01
Hematocrit	42.2		%	37.5 - 51.0	01
MCV	86		fL	79 - 97	01
MCH	30.0		pg	26.6 - 33.0	01
MCHC	34.8		g/dL	31.5 - 35.7	01
RDW	14.6		%	12.3 - 15.4	01
Platelets	242		x10E3/uL	150 - 379	01
Neutrophils	50		%	Not Estab.	01
Lymphs	37		%	Not Estab.	01
Monocytes	5		%	Not Estab.	01
Eos	7		%	Not Estab.	01
Basos	1		%	Not Estab.	01
Neutrophils (Absolute)	2.8		x10E3/uL	1.4 - 7.0	01
Lymphs (Absolute)	2.1		x10E3/uL	0.7 - 3.1	01
Monocytes(Absolute)	0.3		x10E3/uL	0.1 - 0.9	01
Eos (Absolute)	0.4		x10E3/uL	0.0 - 0.4	01
Baso (Absolute)	0.0		x10E3/uL	0.0 - 0.2	01
Immature Granulocytes	0		%	Not Estab.	01
Immature Grans (Abs)	0.0		x10E3/uL	0.0 - 0.1	01
Comp. Metabolic Panel (14)					
Glucose	**128**	**High**	mg/dL	65 - 99	01
Sample is lipemic. This may cause spurious increases in TBili, DBili, AST, ALT, and UIBC (if ordered). Clinical correlation indicated.					
Specimen received hemolyzed. Clinical correlation indicated.					

LabCorp

Patient Report

Patient: EPSTEIN, JEFFREY
DOB: 01/20/1953
Patient ID:
Control ID: F5B31143092
Specimen ID: 257-480-2371-0
Date collected: 09/14/2018 1255 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
BUN	22		mg/dL	8 - 27	01
Creatinine	0.96		mg/dL	0.76 - 1.27	01
eGFR If NonAfricn Am	83		mL/min/1.73	>59	
eGFR If Africn Am	95		mL/min/1.73	>59	
BUN/Creatinine Ratio	23			10 - 24	
Sodium	138		mmol/L	134 - 144	01
Potassium	4.2		mmol/L	3.5 - 5.2	01
Sample is lipemic. This may cause spurious increases in TBili, DBili, AST, ALT, and UIBC (if ordered). Clinical correlation indicated. Specimen received hemolyzed. Clinical correlation indicated.					
Chloride	102		mmol/L	96 - 106	01
Carbon Dioxide, Total	20		mmol/L	20 - 29	01
Calcium	9.4		mg/dL	8.6 - 10.2	01
Protein, Total	6.7		g/dL	6.0 - 8.5	01
Albumin	4.3		g/dL	3.6 - 4.8	01
Globulin, Total	2.4		g/dL	1.5 - 4.5	
A/G Ratio	1.8			1.2 - 2.2	
Bilirubin, Total	0.3		mg/dL	0.0 - 1.2	01
Alkaline Phosphatase	71		IU/L	39 - 117	01
AST (SGOT)	26		IU/L	0 - 40	01
The specimen was lipemic. The lipemia was cleared by ultracentrifugation before testing. However HDL, direct LDL, cholesterol and triglyceride (if ordered) were performed prior to ultracentrifugation.					
ALT (SGPT)	37		IU/L	0 - 44	01
Urinalysis, Routine					
Urinalysis Gross Exam					01
Specific Gravity	1.027			1.005 - 1.030	01
pH	5.5			5.0 - 7.5	01
Urine-Color	Yellow			Yellow	01
Appearance	Clear			Clear	01
WBC Esterase	Negative			Negative	01
Protein	Negative			Negative/Trace	01
Glucose	Negative			Negative	01
Ketones	Negative			Negative	01
Occult Blood	Negative			Negative	01
Bilirubin	Negative			Negative	01
Urobilinogen,Semi-Qn	0.2		EU/dL	0.2 - 1.0	01
Nitrite, Urine	Negative			Negative	01
Microscopic Examination					
Microscopic follows if indicated.					01
PE+Interp(Rfx IFE),S	**Will Follow**				

LabCorp

Patient Report

Patient: EPSTEIN, JEFFREY
DOB: 01/20/1953
Patient ID:
Control ID: F5B31143092
Specimen ID: 257-480-2371-0
Date collected: 09/14/2018 1255 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Lipid Panel					
Cholesterol, Total	**234**	**High**	mg/dL	100 - 199	01
Triglycerides	*1714*	*Alert*	mg/dL	0 - 149	01
Results confirmed on dilution.					
HDL Cholesterol	**19**	**Low**	mg/dL	>39	01
VLDL Cholesterol Cal			mg/dL	5 - 40	
The calculation for the VLDL cholesterol is not valid when triglyceride level is >400 mg/dL.					
LDL Cholesterol Calc			mg/dL	0 - 99	
Triglyceride result indicated is too high for an accurate LDL cholesterol estimation.					
Iron and TIBC					
Iron Bind.Cap.(TIBC)	320		ug/dL	250 - 450	
UIBC	252		ug/dL	111 - 343	01
Iron	68		ug/dL	38 - 169	01
Iron Saturation	21		%	15 - 55	
Testosterone,Free+Weakly Bound					
Testosterone, Serum	**140**	**Low**	ng/dL	264 - 916	01
Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.					
Testost., % Free+Weakly Bound	Will Follow		%	9.0 - 46.0	02
Testost., F+W Bound	Will Follow		ng/dL	40.0 - 250.0	
Vitamin B12 and Folate	**Will Follow**				
FSH and LH					
LH	3.7		mIU/mL	1.7 - 8.6	01
FSH	4.4		mIU/mL	1.5 - 12.4	01
C-Reactive Protein, Cardiac	1.56		mg/L	0.00 - 3.00	01
Relative Risk for Future Cardiovascular Event					
Low				<1.00	
Average				1.00 - 3.00	
High				>3.00	
Hemoglobin A1c					
Hemoglobin A1c	5.5		%	4.8 - 5.6	01
Please Note:					01
Prediabetes: 5.7 - 6.4					
Diabetes: >6.4					
Glycemic control for adults with diabetes: <7.0					
Prostate-Specific Ag, Serum					
Prostate Specific Ag, Serum	0.7		ng/mL	0.0 - 4.0	01

LabCorp

Patient Report

Patient: EPSTEIN, JEFFREY
DOB: 01/20/1953
Patient ID:
Control ID: F5B31143092
Specimen ID: 257-480-2371-0
Date collected: 09/14/2018 1255 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Roche ECLIA methodology. According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.					
TSH	1.290		uIU/mL	0.450 - 4.500	01
Vitamin D, 25-Hydroxy	**20.2**	**Low**	ng/mL	30.0 - 100.0	01
Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2).					
1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press.					
2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.					
Lipoprotein (a)	20		nmol/L	<75	01
Note: Values greater than or equal to 75 nmol/L may indicate an independent risk factor for CHD, but must be evaluated with caution when applied to non-Caucasian populations due to the influence of genetic factors on Lp(a) across ethnicities.					
IGF-1					
Insulin-Like Growth Factor I	137		ng/mL	49 - 188	02
ANA w/Reflex					
ANA Direct	Negative			Negative	01
Homocyst(e)ine, Plasma	14.9		umol/L	0.0 - 15.0	01
Prolactin	**3.9**	**Low**	ng/mL	4.0 - 15.2	01
Thyroxine (T4) Free, Direct, S					
T4,Free(Direct)	1.05		ng/dL	0.82 - 1.77	01
Cortisol	3.7		ug/dL		01
			Cortisol AM	6.2 - 19.4	
			Cortisol PM	2.3 - 11.9	

LabCorp

Patient Report

Patient: EPSTEIN, JEFFREY
DOB: 01/20/1953
Patient ID:
Control ID: F5B31143092
Specimen ID: 257-480-2371-0
Date collected: 09/14/2018 1255 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
DHEA-Sulfate	181.8		ug/dL	30.9 - 295.6	01
Estradiol	28.3		pg/mL	7.6 - 42.6	01
Roche ECLIA methodology					
Uric Acid					
Uric Acid	6.8		mg/dL	3.7 - 8.6	01
Please Note:					01
Therapeutic target for gout patients: <6.0					
Phosphorus	3.6		mg/dL	2.5 - 4.5	01
LDH	213		IU/L	121 - 224	01
GGT	25		IU/L	0 - 65	01
Amylase	37		U/L	31 - 124	01
Ferritin, Serum	**Will Follow**				
Insulin	**47.2**	**High**	uIU/mL	2.6 - 24.9	01
Calcium, Ionized, Serum	5.3		mg/dL	4.5 - 5.6	01
Fibrinogen Activity	330		mg/dL	193 - 507	01
Specimen was ultracentrifuged before testing to remove extreme lipemia. Results should be interpreted with caution.					
Magnesium, RBC	5.4		mg/dL	4.2 - 6.8	02
Plasma NOT separated from cells; may falsely decrease RBC Magnesium levels.					

01	RN	LabCorp Raritan 69 First Avenue, Raritan, NJ 08869-1800	Dir: Araceli B Reyes, MD
02	BN	LabCorp Burlington 1447 York Court, Burlington, NC 27215-3361	Dir: William F Hancock, MD

For inquiries, the physician may contact **Branch: 800-631-5250 Lab:** [redacted]

LabCorp

Patient Report

Specimen ID: 257-480-2232-0
Control ID: F5A31143092

Acct #: 31143092 Phone: [redacted] Rte: 68

EPSTEIN, JEFFREY

Woodson Merrell
44 E 67th St
New York NY 10065

Patient Details
DOB: 01/20/1953
Age(y/m/d): 065/07/25
Gender: M SSN:
Patient ID:

Specimen Details
Date collected: 09/14/2018 1255 Local
Date received: 09/15/2018
Date entered: 09/15/2018
Date reported: 09/16/2018 0808 ET

Physician Details
Ordering:
Referring:
ID: MERRELL
NPI:

General Comments & Additional Information
Total Volume: Not Provided **Fasting:** No

Ordered Items
Ca+PTH Intact

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Ca+PTH Intact					
Calcium	9.5		mg/dL	8.6 - 10.2	01
Specimen received hemolyzed. Clinical correlation indicated.					
PTH, Intact	**71**	**High**	pg/mL	15 - 65	01
Intact PTH					01

Interpretation	Intact PTH (pg/mL)	Calcium (mg/dL)
Normal	15 - 65	8.6 - 10.2
Primary Hyperparathyroidism	>65	>10.2
Secondary Hyperparathyroidism	>65	<10.2
Non-Parathyroid Hypercalcemia	<65	>10.2
Hypoparathyroidism	<15	< 8.6
Non-Parathyroid Hypocalcemia	15 - 65	< 8.6

01 RN LabCorp Raritan
69 First Avenue, Raritan, NJ 08869-1800
Dir: Araceli B Reyes, MD

For inquiries, the physician may contact **Branch:** [redacted] **Lab:** [redacted]

Date Issued: 09/17/18 0916 ET **FINAL REPORT** Page 1 of 1

LabCorp

Patient Report

Specimen ID: 257-480-2715-0
Control ID: END31143092

Acct #: 31143092 Phone: [redacted] Rte: 68

EPSTEIN, JEFFREY
9 E 71ST ST
NEW YORK NY 10021
[redacted]

Woodson Merrell
44 E 67th St
New York NY 10065

Patient Details
DOB: 01/20/1953
Age(y/m/d): 065/07/25
Gender: M SSN:
Patient ID:

Specimen Details
Date collected: 09/14/2018 1255 Local
Date received: 09/15/2018
Date entered: 09/15/2018
Date reported: 09/18/2018 0610 ET

Physician Details
Ordering: W MERRELL
Referring:
ID:
NPI: 1023153509

General Comments & Additional Information
Total Volume: Not Provided **Fasting:** No

Ordered Items
Chlamydia/GC Amplification; Panel 083935; HCV Ab w/Rflx to Verification; RPR, Rfx Qn RPR/Confirm TP

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Chlamydia/GC Amplification					
Chlamydia trachomatis, NAA	Negative			Negative	01
Neisseria gonorrhoeae, NAA	Negative			Negative	01
Panel 083935					
HIV Screen 4th Generation wRfx	Non Reactive			Non Reactive	01
HCV Ab w/Rflx to Verification					
HCV Ab	<0.1		s/co ratio	0.0 - 0.9	01
Comment:					01
Non reactive HCV antibody screen is consistent with no HCV infection, unless recent infection is suspected or other evidence exists to indicate HCV infection.					
RPR, Rfx Qn RPR/Confirm TP					
RPR	Non Reactive			Non Reactive	01

01 RN LabCorp Raritan
69 First Avenue, Raritan, NJ 08869-1800
Dir: Araceli B Reyes, MD

For inquiries, the physician may contact **Branch:** [redacted] **Lab:** [redacted]

Date Issued: 09/18/18 1053 ET

FINAL REPORT

LabCorp

Patient Report

Specimen ID: 257-480-2542-0
Control ID: F5C31143092

Acct #: 31143092 Phone: [redacted] Rte: 68

EPSTEIN, JEFFREY
9 E 71ST ST
NEW YORK NY 10021

Woodson Merrell
44 E 67th St
New York NY 10065

Patient Details
DOB: 01/20/1953
Age(y/m/d): 065/07/25
Gender: M SSN:
Patient ID:

Specimen Details
Date collected: 09/14/2018 1255 Local
Date received: 09/15/2018
Date entered: 09/15/2018
Date reported: 09/18/2018 0823 ET

Physician Details
Ordering: W MERRELL
Referring:
ID: MERRELL
NPI: 1023153509

General Comments & Additional Information
Total Volume: Not Provided

Fasting: No

Ordered Items
Zinc, Whole Blood

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Zinc, Whole Blood	749		ug/dL	440 - 860	01

01 BN LabCorp Burlington
1447 York Court, Burlington, NC 27215-3361
Dir: William F Hancock, MD

For inquiries, the physician may contact **Branch:** [redacted] **Lab:** [redacted]

Date Issued: 09/18/18 1053 ET

FINAL REPORT

LabCorp **Patient Report**

Specimen ID: 257-480-2300-0
Control ID: 25648023000

Acct #: 31143092 Phone: [redacted] Rte: 68

EPSTEIN, JEFFREY
9 EAST 71 STREET
NYC NY 10021

Woodson Merrell
44 E 67th St
New York NY 10065

Patient Details
DOB: 01/20/1953
Age(y/m/d): 065/07/25
Gender: M SSN:
Patient ID:

Specimen Details
Date collected: 09/14/2018 1255 Local
Date received: 09/15/2018
Date entered: 09/15/2018
Date reported: 09/17/2018 2010 ET

Physician Details
Ordering: W MERRELL
Referring:
ID: MERRELL
NPI: 1023153509

Ordered Items
Heavy Metals Profile II, Blood

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Heavy Metals Profile II, Blood					
Lead, Blood	Will Follow		ug/dL	0 - 4	01
Blood Lead Collection Method: Venous Testing performed by Inductively coupled plasma/Mass Spectrometry. Environmental Exposure: WHO Recommendation <20 Occupational Exposure: OSHA Lead Std 40 BEI 30 Detection Limit = 1					
Arsenic, Blood	8		ug/L	2 - 23	01
			Detection Limit = 1		
Mercury, Blood	2.1		ug/L	0.0 - 14.9	01
Environmental Exposure: <15.0 Occupational Exposure: BEI - Inorganic Mercury: 15.0 Detection Limit = 1.0					
Cadmium, Blood	None Detected		ug/L	0.0 - 1.2	01
Environmental Exposure: Nonsmokers 0.3 - 1.2 Smokers 0.6 - 3.9 Occupational Exposure: OSHA Cadmium Std 5.0 BEI 5.0 Detection Limit = 0.5					

01 BN LabCorp Burlington
1447 York Court, Burlington, NC 27215-3361
Dir: William F Hancock, MD

For inquiries, the physician may contact **Branch:** [redacted] **Lab:** [redacted]

Date Issued: 09/18/18 1053 ET **PRELIMINARY REPORT** Page 1 of 1

IMUGEN Reference Diagnostic Division
Oxford Immunotec, Inc. d/b/a IMUGEN
315 Norwood Park South, Norwood MA 02062 • [redacted] • FAX [redacted]

Lyme Antibody Analysis

Submitter:

WOODSON C MERRELL MD
SUITE 1B
44 EAST 67TH STREET
NEW YORK, NY 10065

Ordering Provider: WOODSON C MERRELL MD

Account #: MERW

Patient:

Name: JEFFREY EPSTEIN
Address: 9 EAST 71ST STREET
NEW YORK, NY 10021

D.O.B.: 01/20/1953

Submitter Record #:

IMUGEN Patient #: 2018013061

Antibody Capture Enzyme Immunoassay

Test Date: 09/17/2018

Antigen	Antibody Isotype	Results	
		PLASMA # 13061 Collection Date: 09/14/2018 Receipt Date: 09/17/2018	CSF # Collection Date: Receipt Date:
B. burgdorferi 49736	IgM	<1	
	IgG	<1	
	IgA	<1	

Values reflect the relative amount of *B. burgdorferi*-specific antibody corrected for background.
Normal Range: no antibody detected at <0.8 for IgM and <1 for IgG and IgA.

Immunoblot IgG (Western Blot)

PLASMA # 13061
Test Date: 09/17/2018



Reactive bands are listed in kD of *B. burgdorferi* antigens with which IgG is reactive.
Normal Range: Reactivity to <5 antigens on each blot.

Comments: No IgM, IgG or IgA antibody to *B. burgdorferi* detected by capture EIA; the IgG immunoblot results fall within normal limits.

Interpretation: No serologic evidence of infection with *B. burgdorferi* (Lyme).

Note 1: Results [redacted] be evaluated in conjunction with clinical presentation and other medical and diagnostic findings.
Note 2: A negative result does not exclude the possibility of infection with *Borrelia burgdorferi*. Antibodies may not yet be present at the time of blood sample collection or may not yet be detectable.
Note 3: If the initial LAA test result is negative (i.e. antibodies not detected) and the patient's clinical history strongly suggests infection, the collection of a second sample is strongly recommended.
Note 4: Quantitative antibody capture enzyme immunoassay values can vary two-fold within a test run. Values should not be considered clinically relevant outside of a comparative analysis performed on the same patient on the same test run.
Note 5: These tests were developed and their performance characteristics determined by **IMUGEN**. They have not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. These tests are used for clinical purposes. They should not be regarded as investigational or for research.
Note 6: A positive result may not exclude the possibility of a successfully treated past infection.

Report Date: 09/17/2018 KEW/JAL

Mihae Platt M.D., Ph.D. Director
CLIA number 22D0650196